Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients

Authors: Lukas Schwentner, Achim Wöckel, Jochem König, Wolfgang Janni, Florian Ebner, Maria Blettner, Rolf Kreienberg, Reyn Van Ewijk, for the Brenda study group

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Triple-negative breast cancer (TNBC) remains a challenging topic for clinical oncologists. This study sought to evaluate TNBC versus other breast cancer subtypes with respect to survival parameters. We evaluated possible differences in survival in TNBC by age and by the extent to which evidence-based treatment guidelines were adhered.

Methods

This German retrospective multi-center cohort study included 9156 patients with primary breast cancer recruited from 1992 to 2008.

Results

The rates of guideline adherence are significantly lower in TNBC compared to non-TNBC subtypes. These lower rates of guideline adherence can be observed in all age groups and are most pronounced in the >65 subgroup [<50 (20.9% vs. 42.0%), 50–64 (25.1% vs. 51.1%), and >65 (38.4% vs. 74.6%)]. In TNBC patients of all age groups, disease-free survival and overall survival were associated with an improvement by 100% guideline-adherent adjuvant treatment compared to non-adherence. Furthermore, TNBC patients of all ages had similar outcome parameters if 100% guideline-adherent adjuvant treatment was applied.

Conclusion

The rates of guideline-adherent treatment were significantly lower in TNBC, even though guideline adherence was strongly associated with improved survival. In the case of 100% guideline-adherent treatment, no difference in survival was observed over all the age groups examined, even in the group of >65-year-old TNBC patients.
Appendix
Available only for authorised users
Literature
1.
Badve S, Dabbs DJ, Schnitt SJ, Baehner SL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS: Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011, 24 (2): 157-167. 10.1038/modpathol.2010.200.CrossRefPubMed
2.
Rakha EA, Ellis IO: Triple-negative/basal-like breast cancer: review. Pathology. 2009, 41 (1): 40-47. 10.1080/00313020802563510.CrossRefPubMed
3.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer. 2007, 109 (1): 25-32. 10.1002/cncr.22381.CrossRefPubMed
4.
Hudis CA, Gianni L: Triple-negative breast cancer: an unmet medical need. Oncologist. 2011, 16 (1): 1-11. 10.1634/theoncologist.2010-0301.CrossRefPubMed
5.
Teng YH, Thike AA, Wong NS, Tan PH: Therapeutic targets in triple negative breast cancer-where are we now?. Recent Pat Anticancer Drug Discov. 2011, 6 (2): 196-209. 10.2174/157489211795328521.CrossRefPubMed
6.
Pal SK, Childs BH, Pegram M: Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011, 125 (3): 627-636. 10.1007/s10549-010-1293-1.CrossRefPubMed
7.
Loibl S, Jakisch C, Gade S, Untch M, Paepke S, Kuemmel S, Schneeweiss A, Jakisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa SD, Blohmer JU, Nekljudova K, Mehta K, Von Minckwitz G: Neoadjuvant chemotherapy in the very young breast cancer patients. Cancer Res. 2012, 72 (Suppl. 24): S3-1 (SABCS 2012)-
8.
Boyle P: Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012, 23 (Suppl. 6): vi7-vi12.PubMed
9.
Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G: Characteristics of triple-negative breast cancer in patients with a BRCA 1 mutation: results from a population-based study of young women. J Clin Oncol. 2011, 29 (33): 4373-4380. 10.1200/JCO.2010.33.6446.CrossRefPubMedPubMedCentral
10.
Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8 (3): 138-140.PubMed
11.
Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky MB, Wöckel A: A comparison of international breast cancer guidelines—do the national guidelines differ in treatment recommendations?. Eur J Cancer. 2012, 48 (1): 1-11. 10.1016/j.ejca.2011.06.020.CrossRefPubMed
12.
Kreienberg R, Kopp I, Albert U, Bartsch HH, Beckmann MW, Berg D, Bick A, du Bois A, Budach A, Dunst J, Engel J, Ernst B, Geraedts M, Henscher U, Hölzel D, Jackisch C, König K, Kreipe H, Kühn T, Lebeau A, Leinung S, Link H, Lück HJ, Madjar H, Maiwald A, Maiwald G, Marschner N, Marx M, von Minckwitz G, Naß-Griegoleit I, Possinger K, Reiter A, Sauerbrei W, Schlake W, Schmutzler R, Schreer I, Schulte H, Schulz KD, Souchon R, Thomssen C, Untch M, Wagner U, Weis J, Zemmler T: Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. 2008, Berlin: German Cancer Society
13.
Lancaster T: Econometric methods for the duration of unemployment. Econometrica. 1979, 47: 939-956. 10.2307/1914140.CrossRef
14.
Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R, Rottscholl R, Wöckel A: Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study. Breast Cancer Res Treat. 2012, 132 (3): 1073-1080. 10.1007/s10549-011-1935-y.CrossRefPubMed
15.
Joensuu H, Gligorov J: Adjuvant treatments for triple-negative breast cancers. Ann Oncol. 2012, 23 (6): vi50-
16.
Aapro M, Wildiers H: Triple-negative breast cancer in the older population. Ann Oncol. 2012, 23 (6): vi52-vi55.PubMed
17.
Hamaker ME, Schreurs WH, Uppelschoten JM, Smorenburg CH: Breast cancer in the elderly: retrospective study on diagnosis and treatment according to national guidelines. Breast J. 2009, 15: 26-33. 10.1111/j.1524-4741.2008.00667.x.CrossRefPubMed
18.
Wöckel A, Kurzeder C, Geyer V, Novopasphenny I, Wolters R, Wischnewsky M, Kreienberg R, Varga D: Effects of guideline adherence in primary breast cancer-A 5 year multi-center cohort study of 3976 patients. Breast. 2010, 19: 120-127. 10.1016/j.breast.2009.12.006.CrossRefPubMed
19.
Hebert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G: Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodal negative breast cancer. J Clin Oncol. 2004, 22 (18): 3685-3693. 10.1200/JCO.2004.07.018.CrossRefPubMed
20.
Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R: Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study. Ann Oncol. 2010, 21 (4): 748-753. 10.1093/annonc/mdp364.CrossRefPubMed
21.
Schwentner L, Wolters R, Wischnewsky MB, Kreienberg R, Wöckel A: Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast. 2012, 21 (2): 171-177. 10.1016/j.breast.2011.09.007.CrossRefPubMed
22.
Schwentner L, Van Ewijk R, Kurzeder C, Hoffman I, König J, Kreienberg R, Blettner M, Wöckel A: Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-center cohort study of 9433 patients. Eur J Cancer. 2013, 49 (3): 553-563. 10.1016/j.ejca.2012.08.011.CrossRefPubMed
23.
Varga D, Wischnewsky M, Atassi Z, Wolters R, Geyer V, Strunz K, Kreienberg R, Wöckel A: Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients?. Oncology. 2010, 78 (3–4): 189-195.CrossRefPubMed
24.
Janssen-Heijnen ML, Maas HA, Lemmens VE, Houterman S, Louwman WJ, Verheij CD, Coebergh JW: The correlation of age and comorbidity with therapy and survival in cancer patients in North-Brabant and North-Limburg, 1995–2001. Ned Tijdschr Geneeskd. 2005, 149 (30): 1686-1690.PubMed
25.
DeMichele A, Putt M, Zhang Y, Glick JH, Norman S: Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer. 2003, 97 (9): 2150-2159. 10.1002/cncr.11338.CrossRefPubMed
26.
Craft PS, Buckingham JM, Dahlstrom JE, Beckmann KR, Zhang Y, Stuart-Harris R, Jacob G, Roder D, Tait N: Variation in the management of early breast cancer in rural and metropolitan centres: implications for the organisation of rural cancer services. Breast. 2010, 19 (5): 396-401. 10.1016/j.breast.2010.03.032.CrossRefPubMed
27.
Goldhirsch A, Wod WC, Gelber RD, Coates AS, Thürliman B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18 (7): 1133-1144. 10.1093/annonc/mdm271.CrossRefPubMed
Metadata
Title
Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients
Authors
Lukas Schwentner
Achim Wöckel
Jochem König
Wolfgang Janni
Florian Ebner
Maria Blettner
Rolf Kreienberg
Reyn Van Ewijk
for the Brenda study group
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-487

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer

Research article

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis

Research article

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia

Research article

NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients

Research article

Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9

Research article

Involvement of nitric oxide synthase in matrix metalloproteinase-9- and/or urokinase plasminogen activator receptor-mediated glioma cell migration
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits